{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T12:43:31Z","timestamp":1793105011460,"version":"4.5.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,25]],"date-time":"2022-01-25T00:00:00Z","timestamp":1643068800000},"content-version":"vor","delay-in-days":24,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.clinthera.2021.11.009","type":"journal-article","created":{"date-parts":[[2022,1,25]],"date-time":"2022-01-25T00:57:14Z","timestamp":1643072234000},"page":"98-110.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Effect of Acid Suppression Therapy on the Safety and Efficacy of Plecanatide: Analysis of Randomized Phase III Trials"],"prefix":"10.1016","volume":"44","author":[{"given":"Baharak","family":"Moshiree","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7620-2878","authenticated-orcid":false,"given":"Philip","family":"Schoenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Franklin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Rezaie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2021.11.009_bib0001","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/ajg.2015.67","article-title":"The spectrum of constipation-predominant irritable bowel syndrome and chronic idiopathic constipation: US survey assessing symptoms, care seeking, and disease burden","volume":"110","author":"Heidelbaugh","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.clinthera.2021.11.009_bib0002","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1007\/s12325-017-0633-5","article-title":"The Better Understanding and Recognition of the Disconnects, Experiences, and Needs of patients with Chronic Idiopathic Constipation (BURDEN-CIC) study: results of an online questionnaire","volume":"34","author":"Harris","year":"2017","journal-title":"Adv Ther"},{"key":"10.1016\/j.clinthera.2021.11.009_bib0003","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1053\/j.gastro.2005.11.061","article-title":"Functional bowel disorders","volume":"130","author":"Longstreth","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinthera.2021.11.009_bib0004","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1038\/ajg.2011.164","article-title":"Prevalence of, and risk factors for, chronic idiopathic constipation in the community: systematic review and meta-analysis","volume":"106","author":"Suares","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.clinthera.2021.11.009_bib0005","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.pharmthera.2004.08.007","article-title":"Uroguanylin and guanylin peptides: pharmacology and experimental therapeutics","volume":"104","author":"Forte","year":"2004","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2021.11.009_bib0006","doi-asserted-by":"crossref","DOI":"10.1177\/1756284818777945","article-title":"Plecanatide: a new guanylate cyclase agonist for the treatment of chronic idiopathic constipation","volume":"11","author":"Rao","year":"2018","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.clinthera.2021.11.009_bib0007","series-title":"Trulance [package insert]","year":"2020"},{"key":"10.1016\/j.clinthera.2021.11.009_bib0008","doi-asserted-by":"crossref","first-page":"e00295","DOI":"10.1002\/prp2.295","article-title":"Therapeutically targeting guanylate cyclase-C: computational modeling of plecanatide, a uroguanylin analog","volume":"5","author":"Brancale","year":"2017","journal-title":"Pharmacol Res Perspect"},{"key":"10.1016\/j.clinthera.2021.11.009_bib0009","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1073\/pnas.94.6.2705","article-title":"Regulation of intestinal uroguanylin\/guanylin receptor-mediated responses by mucosal acidity","volume":"94","author":"Hamra","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clinthera.2021.11.009_bib0010","doi-asserted-by":"crossref","first-page":"213","DOI":"10.4292\/wjgpt.v6.i4.213","article-title":"Plecanatide and dolcanatide, novel guanylate cyclase-C agonists, ameliorate gastrointestinal inflammation in experimental models of murine colitis","volume":"6","author":"Shailubhai","year":"2015","journal-title":"World J Gastrointest Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2021.11.009_bib0011","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2147\/CEG.S145668","article-title":"Profile of plecanatide in the treatment of chronic idiopathic constipation: design, development, and place in therapy","volume":"12","author":"Sharma","year":"2019","journal-title":"Clin Exp Gastroenterol"},{"key":"10.1016\/j.clinthera.2021.11.009_bib0012","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1023\/A:1018827003641","article-title":"Effect of omeprazole 40 mg once daily on intraduodenal and intragastric pH in H. pylori-negative healthy subjects","volume":"42","author":"Gan","year":"1997","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.clinthera.2021.11.009_bib0013","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1007\/BF02234376","article-title":"Randomized, placebo-controlled trial of gastric acid-lowering therapy on duodenal polyposis and relative adduct labeling in familial adenomatous polyposis","volume":"44","author":"Wallace","year":"2001","journal-title":"Dis Colon Rectum"},{"key":"10.1016\/j.clinthera.2021.11.009_bib0014","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1177\/2050640615600114","article-title":"Symptom burden and consulting behavior in patients with overlapping functional disorders in the US population","volume":"4","author":"Vakil","year":"2016","journal-title":"United European Gastroenterol J"},{"key":"10.1016\/j.clinthera.2021.11.009_bib0015","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1038\/ajg.2015.156","article-title":"How do US gastroenterologists use over-the-counter and prescription medications in patients with gastroesophageal reflux and chronic constipation?","volume":"110","author":"Menees","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.clinthera.2021.11.009_bib0016","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1177\/1756283X17734697","article-title":"Randomized clinical trial: efficacy and safety of plecanatide in the treatment of chronic idiopathic constipation","volume":"10","author":"DeMicco","year":"2017","journal-title":"Therap Adv. Gastroenterol."},{"key":"10.1016\/j.clinthera.2021.11.009_bib0017","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/ajg.2016.611","article-title":"A randomized phase III clinical trial of plecanatide, a uroguanylin analog, in patients with chronic idiopathic constipation","volume":"112","author":"Miner","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.clinthera.2021.11.009_bib0018","doi-asserted-by":"crossref","first-page":"920","DOI":"10.3109\/00365529709011203","article-title":"Stool form scale as a useful guide to intestinal transit time","volume":"32","author":"Lewis","year":"1997","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.clinthera.2021.11.009_bib0019","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/s41395-018-0026-7","article-title":"Efficacy, safety, and tolerability of plecanatide in patients with irritable bowel syndrome with constipation: results of two phase 3 randomized clinical trials","volume":"113","author":"Brenner","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.clinthera.2021.11.009_bib0020","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1038\/s41395-018-0114-8","article-title":"Comment on meta analysis by Shah et\u00a0al","volume":"113","author":"Griffin","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.clinthera.2021.11.009_bib0021","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1016\/j.clinthera.2020.05.012","article-title":"Evaluation of plecanatide for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation in patients 65 years or older","volume":"42","author":"Menees","year":"2020","journal-title":"Clin. Ther."},{"key":"10.1016\/j.clinthera.2021.11.009_bib0022","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s40264-014-0144-0","article-title":"Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update","volume":"37","author":"Wedemeyer","year":"2014","journal-title":"Drug Saf"},{"key":"10.1016\/j.clinthera.2021.11.009_bib0023","doi-asserted-by":"crossref","first-page":"769","DOI":"10.2165\/00002018-200629090-00002","article-title":"Pharmacokinetic drug interaction profiles of proton pump inhibitors","volume":"29","author":"Blume","year":"2006","journal-title":"Drug Saf"},{"key":"10.1016\/j.clinthera.2021.11.009_bib0024","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1046\/j.1365-2036.2003.01431.x","article-title":"Pharmacokinetics of budesonide controlled-release capsules when taken with omeprazole","volume":"17","author":"Edsb\u00e4cker","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2021.11.009_bib0025","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1177\/0194599816648298","article-title":"Adverse event reporting for proton pump inhibitor therapy: an overview of systematic reviews","volume":"155","author":"Abramowitz","year":"2016","journal-title":"Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.clinthera.2021.11.009_bib0026","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s11894-007-0044-x","article-title":"Drug-induced diarrhea","volume":"9","author":"Abraham","year":"2007","journal-title":"Curr Gastroenterol Rep"},{"key":"10.1016\/j.clinthera.2021.11.009_bib0027","first-page":"44","article-title":"Bowel symptoms in patients that receive proton pump inhibitors. Results of a multicenter survey in Mexico","volume":"84","author":"Schmulson","year":"2019","journal-title":"Rev Gastroenterol Mex"},{"key":"10.1016\/j.clinthera.2021.11.009_bib0028","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/j.1365-2362.2010.02419.x","article-title":"Effects of long-term PPI treatment on producing bowel symptoms and SIBO","volume":"41","author":"Compare","year":"2011","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.clinthera.2021.11.009_bib0029","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s00535-020-01713-8","article-title":"Solving the questions regarding 5-aminosalitylate formulation in the treatment of ulcerative colitis","volume":"55","author":"Naganuma","year":"2020","journal-title":"J Gastroenterol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291821004628?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291821004628?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:55:45Z","timestamp":1758963345000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291821004628"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S0149291821004628"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2021.11.009","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Effect of Acid Suppression Therapy on the Safety and Efficacy of Plecanatide: Analysis of Randomized Phase III Trials","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2021.11.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}